MannKind enrollment complete in phase 3 study of inhaled insulin

By Lisa Kerner

Charlotte, N.C., Sept. 14 - MannKind Corp. said it completed enrollment in its pivotal long-term phase 3 study of Technosphere Insulin in patients with type 1 and type 2 diabetes.

The investigational inhaled insulin formulation is delivered using MannKind's proprietary inhaler to patients with diabetes mellitus.

More than 1,800 subjects are enrolled in the open-label, randomized study evaluating the pulmonary safety of Technosphere Insulin in patients with type 1 and type 2 diabetes as well as a subgroup of patients without diabetes.

Previous studies showed no adverse effects on lung function, according to the Valencia, Calif.-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.